Thompson Siegel & Walmsley LLC increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,422,482 shares of the company’s stock after buying an additional 49,885 shares during the period. Thompson Siegel & Walmsley LLC owned about 0.24% of Teva Pharmaceutical Industries Limited worth $80,475,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in TEVA. Bronfman E.L. Rothschild L.P. increased its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the period. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the period. FNY Managed Accounts LLC bought a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth approximately $123,000. Sterling Investment Advisors Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. Finally, Cutler Capital Management LLC bought a new stake in Teva Pharmaceutical Industries Limited during the second quarter worth approximately $133,000. Institutional investors own 56.87% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.25% during mid-day trading on Friday, reaching $15.90. 20,045,149 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $23.15 and a 200-day moving average price of $29.75. Teva Pharmaceutical Industries Limited has a 1-year low of $15.75 and a 1-year high of $52.66. The stock’s market cap is $16.15 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business posted $1.25 earnings per share. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.14%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/02/teva-pharmaceutical-industries-limited-teva-stake-boosted-by-thompson-siegel-walmsley-llc.html.

A number of research firms have commented on TEVA. Jefferies Group LLC restated a “hold” rating and set a $26.00 price target (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and set a $28.00 price target (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Sanford C. Bernstein downgraded shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $42.00 to $28.00 in a research report on Friday, August 4th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price (down from $31.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Finally, Maxim Group reiterated a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Four analysts have rated the stock with a sell rating, twenty have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $34.50.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.